Our lead candidate is Lasofoxifene
Unique Selective Estrogen Receptor Modulator (SERM) in Phase 3 Clinical Trials
Extensively studied in post-menopausal osteoporosis treatment and prevention and vulvovaginal atrophy (VVA)
Sermonix was founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulators.
Extensively studied for the treatment and prevention of postmenopausal osteoporosis and treating symptoms of vulvovaginal atrophy (VVA).
Sermonix announces the signing of a license agreement with Ligand Pharmaceuticals Incorporated (LGND LLC) for the development and commercialization of oral lasofoxifene.